Financial Gravity Asset Management’s Cytokinetics CYTK Stock Holding History

Financial Gravity Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2	Closed	-$109	–	1493
2024 Q1	$109	Buy	+2	New	+$155	﹤0.01%	962
2019 Q4	$11K	Sell	94 -10	-10%	-$103	0.01%	1172
2019 Q3	$1K	Hold	104	–	–	﹤0.01%	1004
2019 Q2	$1K	Hold	104	–	–	﹤0.01%	1025
2019 Q1	$1K	Buy	+104	New	+$765	﹤0.01%	1069
2018 Q3	$1K	Sell	109 -6	-5%	-$48	﹤0.01%	1103
2018 Q2	$1K	Sell	115 -4	-3%	-$33	﹤0.01%	1127
2018 Q1	$1K	Buy	+119	New	+$1.02K	﹤0.01%	1101

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Financial Gravity Asset Management's CYTK Position: Q2 2024 in Review

Financial Gravity Asset Management sold out of Cytokinetics (CYTK) in Q2 2024, closing a stake of 2 shares — an estimated $109 sold.

Financial Gravity Asset Management first reported a position in CYTK in Q1 2018 and held it in 8 quarters. The position peaked at $11K in Q4 2019. 344 funds tracked by Wall St. Rank hold CYTK as of Q2 2024.

Financial Gravity Asset Management reported no remaining Cytokinetics position as of Q2 2024 after selling out during the quarter.
Financial Gravity Asset Management sold 2 Cytokinetics shares in Q2 2024, an estimated $109.
Financial Gravity Asset Management first reported a position in Cytokinetics in Q1 2018 and held it in 8 quarters.
Financial Gravity Asset Management's Cytokinetics position peaked at $11K in Q4 2019.
344 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2024.

Based on Financial Gravity Asset Management's 13F filing for Q2 2024, filed 6 Aug 2024.